Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 20 1 2026 02 09 1 13 Forouzan Bahmani Department of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran Farhad Zaker Department of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran Bahram Chahardouli Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Majid Safa Department of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran Nasrin Alizadghandforoush Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Saeed Mohammadi Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Mohsen Nikbakht Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Shahrbano Rostami Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Ghasem Janbabaei Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2025 07 16 2025 11 17 Background: Although Wilms’ tumor 1 (WT1) mRNA overexpression is frequently observed in myelodysplastic neoplasms (MDS), its clinical and molecular significance remains incompletely defined across diverse populations; this study is the first to evaluate WT1 expression in Iranian patients with MDS. Materials and Methods: WT1 expression was assessed in 58 MDS patients using an ELN-certified quantitative RT-PCR assay. Associations with clinical subtype, hematologic features, cytogenetic profiles, and molecular mutations were analyzed. Survival outcomes were evaluated using Kaplan–Meier and Cox regression analyses. Results: WT1 overexpression was detected in 79.3% of patients and was significantly associated with advanced subtypes (MDS-EB1/EB2) and higher IPSS-R risk groups. Elevated WT1 levels correlated with an increased bone marrow (BM) blast percentage (P < 0.01). Although cytogenetic abnormalities were more frequent in patients with WT1 overexpression, the association did not reach statistical significance. No significant correlations were observed with peripheral blood (PB) cytopenias or mutations in RNA splicing genes. Importantly, WT1 overexpression was associated with shorter overall survival (OS) and progression-free survival (PFS). However, in multivariate analysis, ≥10% BM blasts and an abnormal karyotype remained independent predictors of poor outcome, whereas WT1 overexpression itself was not independently prognostic. Conclusion: WT1 overexpression in MDS is associated with advanced disease features and poorer survival, though it is not an independent prognostic value. Its measurement may complement existing risk stratification, particularly in resource-limited settings. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2482 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2482/1127

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 20 1 2026 02 09 46 58 Mahdi Alaee Shahid Rajaee Hospital, Qazvin University of Medical Sciences, Qazvin, Iran Meysam Moulaee Department of Biochemistry, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran Kimia Taebi 1) Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran 2)USERN Office, Qazvin University of Medical Sciences, Qazvin, Iran Ahoura Haghi Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy Maryam Hormozi Department of Biochemistry, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran Mehdi Azad Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran 2025 01 23 2025 12 01 Hepatocellular carcinoma (HCC) is a crucial health concern worldwide, representing a leading cause of cancer-related mortality and the most common form of primary liver cancer. The aggressive nature of HCC is mainly due to its high intention for invasion and metastasis, processes that are regulated by a complex network of genetic and molecular pathways. Among the critical regulators of these processes is microRNA-21 (miR-21), a small non-coding RNA that has been implicated in various oncogenic activities. This review provides a comprehensive analysis of the role of miR-21 in promoting HCC metastasis progression, with a particular focus on its interaction with key signaling pathways, including the PTEN/PI3K/AKT, PDCD4/AP-1, RECK/MMP, and TIMP-3 axes. By targeting tumor suppressors, miR-21 facilitates epithelial-to-mesenchymal transition (EMT), invasion, and metastasis of HCC cells. Understanding the molecular mechanisms regulated by miR-21 not only sheds light on the pathogenesis of HCC but also highlights possible therapeutic targets for combating this aggressive cancer. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2388 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2388/1119

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 20 1 2026 02 09 97 102 Shahabodin Babaeifard Department of Oral and Maxillofacial Medicine, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran Mohaddese Marzban School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Ghazaleh Kheiri School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Leyla Sharifi Aliabadi Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Ghazal Razani Hematologic Malignancies Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran. Maryam Barkhordar Hematologic Malignancies Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2025 12 19 2026 01 27 Oral lichen planus (OLP) is a chronic, T-cell-mediated inflammatory disease of the oral mucosa, notable for its symptomatic burden and potential for malignant transformation. While corticosteroids and immunosuppressants remain the standard of care, their transient efficacy and adverse effect profile underscore a significant unmet clinical need. Mesenchymal stem cells (MSCs), with their multifaceted immunomodulatory and regenerative capabilities, are emerging as a compelling therapeutic alternative. This editorial synthesizes current evidence, positing that MSCs can fundamentally disrupt the immunopathogenic cycle of OLP. We explore the mechanisms by which MSCs re-establish immune tolerance and promote tissue repair, and we critically assess the translational pathway from preclinical models to clinical application. Despite promising results, the journey to clinical adoption necessitates overcoming hurdles in standardization, delivery, and safety profiling. We argue that MSC-based therapy represents not merely an incremental improvement, but a potential paradigm shift towards a curative strategy for this recalcitrant disease. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2615 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2615/1126

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 20 1 2026 02 09 103 109 EN Zahra Keshavarz Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran Alireza Zangooie 1) Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2) Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran Elias Sadooghi Rad Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran Roya Bojaran Department of Pathology, Vali-Asr Hospital, Birjand University of Medical Sciences, Birjand, Iran Zahra Salehi 1) Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2025 12 02 2026 01 06 Paraneoplastic pemphigus (PNP) is a rare, severe autoimmune mucocutaneous disorder most commonly associated with lymphoproliferative malignancies. Here, we report the first documented case of PNP as a paraneoplastic manifestation of multiple myeloma (MM). A 61-year-old male with MM developed widespread mucocutaneous ulcerations shortly after his eleventh chemotherapy cycle, initially suspected to represent Stevens–Johnson syndrome. Clinical examination revealed diffuse skin peeling, mucosal involvement of the eyes, oral cavity, and genital region, and a positive Nikolsky sign. Laboratory evaluation demonstrated acute kidney injury requiring hemodialysis. Despite initial treatment with high-dose intravenous immunoglobulin, lesions persisted. Skin biopsy revealed lichenoid lymphocytic infiltration, basal vacuolar changes, subcorneal and suprabasal acantholysis, and keratinocyte dyskeratosis, confirming PNP. Viral serologies were negative, supporting the autoimmune etiology. The patient was subsequently treated with rituximab, resulting in significant improvement of cutaneous lesions over three months, with residual post-inflammatory hyperpigmentation. This case emphasizes the importance of early recognition and accurate differentiation of PNP from other blistering disorders in patients with underlying hematologic malignancies. Importantly, this represents the first reported instance of PNP presenting as a paraneoplastic manifestation of MM, highlighting the need for awareness of atypical autoimmune syndromes in this population https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2601 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2601/1122

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 20 1 2026 02 09 14 29 Padideh Oghab Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Ali Erfan Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Mohadese Poorpoone Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Mohammadsaleh Peikar Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 2025 05 21 2025 09 14 Background: Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) are rare blood cancers with poorer survival in adolescents and young adults (AYAs) than in children. Pediatric-inspired regimens like CALGB 10403 have improved outcomes in AYAs. This study evaluated the effectiveness, feasibility, and treatment-related toxicities of CALGB 10403 in AYAs with ALL/LBL treated at Seyed Al-Shohada Hospital, Isfahan, Iran, from December 2021 to May 2024 Materials and Methods: AYAs aged 17-39 with newly diagnosed ALL/LBL (excluding Burkitt, Ph+, and prior treatment) were included.  Baseline characteristics and outcomes of interest (induction response, event-free and overall survivals) were collected.  Induction response was assessed via bone marrow (ALL) or CT scan/biopsy (LBL). Minimal residual disease (MRD) was evaluated by flow cytometry. Treatment-related toxicities were monitored and graded per CTCAE criteria. The feasibility of implementing the CALGB 10403 protocol was evaluated by measuring treatment delays. Results: Seventeen AYA patients with newly diagnosed ALL/LBL (median age 21) were enrolled, mostly male (14/17). Fourteen had ALL, and three had LBL. Extramedullary involvement was seen in 29%, including lymphadenopathy, bulky mediastinal masses, and CNS involvement. Sixteen patients (94%) achieved remission, with no deaths during the induction course. One-year EFS and OS were 77% and 100%, respectively. Common toxicities included hyperbilirubinemia, elevated transaminases, and infections. Treatment delays, mainly from non-adherence, occurred in 53%. Eight patients achieved MRD negativity after Course I. Conclusion: This study provides insights into the first Iranian experience with the CALGB 10403 protocol for AYAs with ALL/LBL, a regimen that has demonstrated encouraging survival outcomes in U.S. trials. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2458 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2458/1116

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 20 1 2026 02 09 59 77 EN Maeda Mohammad Iraqi Center of Cancer and Medical Genetics Research, Mustansiriyah University, Baghdad, Iraq Zaynab Abdulganii Iraqi Center of Cancer and Medical Genetics Research, Mustansiriyah University, Baghdad, Iraq Aous Almzaien Iraqi Center of Cancer and Medical Genetics Research, Mustansiriyah University, Baghdad, Iraq Ahmed Al-Shammari Iraqi Center of Cancer and Medical Genetics Research, Mustansiriyah University, Baghdad, Iraq Ayser Ahmed Iraqi Center of Cancer and Medical Genetics Research, Mustansiriyah University, Baghdad, Iraq Hiba Shaker https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2069 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2069/1065

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2025 01 21 50 59 EN Hessyani Raranta Department of Clinical Laboratory, Prof. Dr. R. D. Kandou Manado Hospital, Jl. Raya Tanawangko No.56, Malalayang Satu Barat, Malalayang, Manado, North Sulawesi, Indonesia 95262 Purwanto Adipireno Department of Clinical Pathology, Faculty of Medicine, Diponegoro University, Semarang, Central Java, Indonesia Indranila Samsuria Department of Clinical Pathology, Faculty of Medicine, Diponegoro University, Semarang, Central Java, Indonesia 2023 08 11 2024 08 21 RET-He is a cost-effective parameter to assess iron status in CKD, but further research is necessary to assess its correlation with existing parameters. This study attempted to investigate the correlation between RET-He, iron status, and erythrocyte indices among CKD patients. Materials and Methods: A cross-sectional study involving 110 CKD patients who underwent routine hematology and iron profile tests (serum iron/SI, total iron binding capacity/TIBC, transferrin saturation/TSAT, and ferritin). RET-He was then measured using a Sysmex XN-1000 hematology analyzer. Statistical tests were used to define the correlation between RET-He), iron status, and erythrocyte indices. Results: There was a significant positive correlation between RET-He and SI (r = 0.349; p = 0.000), TSAT (r = 0.393; p = 0.000), and ferritin (r = 0.279; p = 0.003). Among CKD patients with excess iron levels, there was a moderate correlation between RET-He and TSAT (r = 0.404; p = 0.000). Conclusion: The study found a significant correlation between RET-He levels and iron status markers in CKD patients. RET-He is recommended as an additional parameter to assess iron status and as an additional method to estimate TSAT and ferritin levels, especially in settings where chemistry analyzers are unavailable. Further research is required to establish RET-He cut-off values for identifying excessive iron levels in CKD patients.   https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2072 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2072/1066

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2025 01 21 60 68 Tanaz Bahri 1)Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Mojtaba Azari Alanjeq Urmia University of Medical Sciences, urmiah, Iran Mohammad Vaezi 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Ghasem Janbabaei Mollah 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran Fatemeh Tajik Rostami 1)Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Maryam Barkhordar 1)Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Morteza Azari Alanjeq Urmia University of Medical Sciences, Urmiah, Iran Mohammad Biglari 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Sahar Tavakoli Shiraji 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran Soroush Rad 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Davoud Babakhani 1) Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran Mohammadreza Rostami 1)Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran Seied Asadollah Mousavi 1)Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Hosein Kamranzadeh Foumani 1) Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran 2)Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran Ardeshir Ghavamzadeh Cancer and Cell Therapy Research Center, Tehran University of Medical Sciences, Tehran, Iran 2024 05 28 2024 10 14 for acute leukemia, though outcomes in older patients remain suboptimal due to higher non-relapse mortality (NRM) and relapse rates. Innovations in conditioning regimens and supportive care have made HSCT accessible to patients over 50, but age-related disparities in outcomes persist. Materials and Methods: This 10-year retrospective cohort study reviewed all patients who underwent first-time allogeneic HSCT for acute leukemia. Patients were stratified by age at HSCT (≥ 50 years and < 50 years), and outcomes were assessed for overall survival (OS), disease-free survival (DFS), NRM, and relapse incidence (RI). Results: Of the 1199 patients, 152 were 50 years or older. Five-year OS rates were markedly lower in patients ≥ 50 years compared to younger patients (48.70% vs. 59.35%; P= 0.024 for AML and 23.60% vs. 41.96%; P= 0.025 for ALL). Moreover, older patients demonstrated significantly higher NRM rates (35.95% vs. 23.53%; P= 0.045 for AML and 78.14% vs. 26.76%; P= 0.005 for ALL) and a notably increased incidence of grade III-IV acute graft-versus-host disease (aGVHD). Interestingly, no significant differences were observed between the two age groups regarding DFS rates and RI. Conclusion: Older acute leukemia patients undergoing allogeneic HSCT face significant challenges, including elevated NRM and GVHD rates. While relapse rates were comparable, survival outcomes favored the younger cohort. These findings emphasize the need for age-adapted transplantation strategies, using reduced-intensity conditioning (RIC) regimens and further research to refine risk stratification and improve management approaches for older patients. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2252 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2252/1067

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2023 08 21 69 74 Saeed Nateghi Department of Cardiology, Baharloo Hospital, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran Aziz Rasooli Department of Emergency Medicine, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran Leila Moadabshoar Head of Prevention and Cancer Control Group, Ministry of Health and Medical Education, Tehran, Iran Zahra Panahi 4Department of Perinatology, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran Mohammadreza Rostami 1)Research Institute for Oncology, Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran 2)Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 2023 06 26 2023 07 18 Hematopoietic stem cell transplantation (HSCT) is considered a potentially curative treatment for several malignant and non-malignant hematologic disorders including transfusion-dependent thalassemia (TDT). However, HSCT is associated with short-term and long-term complications. One of the recognized causes of morbidity and mortality in TDT patients is heart-related complications. Additionally, cardiac involvement is likely to be more common in patients who proceed to HSCT. So the risks of cardiac complications should be carefully weighed against the advantages of the primary disease cure. This review aims to discuss the cardiac considerations that should be kept in mind in TDT patients going through the path of HSCT. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2057 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2057/1072

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2025 01 21 75 80 Saeid Anvari 1)Department of Hematology and Medical Oncology, Guilan University of Medical Sciences, Rasht, Iran 2)Regenerative Medicine, Organ Procurement and Transplantation Multi-Disciplinary Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran Amirhossein Larijani 1)Regenerative Medicine, Organ Procurement and Transplantation Multi-Disciplinary Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran 2)Student Research Committee, Guilan University of Medical Sciences, Rasht, Iran Nasim Ghorbannejad Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran 2023 12 25 2024 08 12 Thrombotic thrombocytopenic purpura (TTP) is a medical condition characterized by a decreased activity of the ADAMTS13 protease,  responsible for cleaving the von Willebrand factor. It contributes to thrombotic microangiopathy. In this report, we described a case of TTP  followed by significant adverse effects during therapeutic plasma exchange (TPE) treatment. The patient received TPE with a time interval from plasma transfusion. A 30-year-old female was evaluated for headaches and bruises on her arms and legs. Laboratory testing revealed thrombocytopenia and anemia. The identification of thrombocytopenia with severe schistocytosis was verified by the analysis of a peripheral blood smear. After confirming a diagnosis of TTP, TPE was performed as therapy. To avoid the complications arising during the previous TPE sessions, we conducted plasma exchange with albumin followed by FFP injection, with a six-hour interval between them. This strategy successfully alleviated the patient's symptoms. Therapeutic plasma exchange (TPE) with a time interval from plasma transfusion can be successfully used in patients with severe TPE complications. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2145 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2145/1073

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2025 01 21 81 85 EN Esra Cengiz Şanlıurfa Mehmet Akif İnan Education and Training Hospital, Şanlıurfa, Turkiye Muruvvet Aydin Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye Ahmet Gunes Ankara Etlik City Hospital, Department of Hematology, Ankara, Turkiye Funda Ceran Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye Simten Dagdas Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye Gulsum Ozet Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkiye 2023 08 22 2024 02 04 Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare, aggressive hematologic neoplasms. Awareness about this neoplasm has increased after it was defined as a clonal plasmacytoid dendritic cell disease under histiocytic/dendritic cell neoplasms in the World Health Organization 2022 classification of myeloid and Histiocytic/Dendritic Neoplasms1. Therapies include chemotherapy or immunotherapy2-4 though stem cell transplantation (SCT) is the best consolidative approach in eligible patients5. Here, we present one intensive therapy-ineligible and two intensive-therapy-eligible patients with different presentations of BPDCN. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2075 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2075/1070

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 1 2025 01 21 86 92 EN Ilya Kolobaev 1)P.A.Hertzen Moscow Oncology Research Institute, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Moscow, Russia 2) A.Tsyb Medical Radiological Research Center, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia Vladimir Usachev A.Tsyb Medical Radiological Research Center, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia Ilya Klabukov 1)Department of Urology and Operative Nephrology, Peoples’ Friendship University of Russia (RUDN University), Moscow, Russia 2)National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia 3)Obninsk Institute for Nuclear Power Engineering, National Research Nuclear University MEPhI, Obninsk, Russia Grigoriy Afonin A.Tsyb Medical Radiological Research Center, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia Oleg Aleksandrov P.A.Hertzen Moscow Oncology Research Institute, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Moscow, Russia Anna Usacheva A.Tsyb Medical Radiological Research Center, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia Stanislav Shklyaev A.Tsyb Medical Radiological Research Center, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia Lyudmila Grivtsova A.Tsyb Medical Radiological Research Center, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia Dmitry Kabanov P.A.Hertzen Moscow Oncology Research Institute, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Moscow, Russia Natalia Rubtsova P.A.Hertzen Moscow Oncology Research Institute, National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Moscow, Russia Peter Shegay National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia Sergei Ivanov A.Tsyb Medical Radiological Research Center, National Medical Research Radiological Ce